Shikonin markedly decreased expression not only of AR, but also PSA, a widely used serologic marker for prostate cancer burdens and an indicator of therapeutic efficacy and recurrence (16), and inhibited growth of AR-positive human prostate cancer cells. The gene discussed is AR; the disease is prostate cancer.